Relypsa Inc (NASDAQ:RLYP) has proved to be a great short-term investment and James Dondero is one of those who profited, as his fund, Highland Capital Management has recently initiated a new position. According to a filing with the Securities and Exchange Commission, Dondero and Highland Capital have amassed 5.91 million shares, which amount to approximately 13.2% of the company’s common stock.
A biopharmaceutical company developing gastrointestinal medicines, Relypsa Inc (NASDAQ:RLYP) is set to be acquired by the Swiss-based Galenica Group for $32 per share, which valued as the company at $1.53 billion. Relypsa will be merged with Galenica’s Vifor Pharma division and later be spun off into a public company that will be one of the largest pharmaceutical company focused on nephrology, cardiology and gastroenterology medicine. One of the main attractions for Galenica was Relypsa’s Veltassa, an FDA-approved treatment for hyperkalemia. With AstraZeneca plc (ADR) (NYSE:AZN)’s candidate out of the game, Veltassa could become the leader in a $6 billion market.
At the end of the first quarter, some 33.4% of Relypsa Inc (NASDAQ:RLYP)’s common stock was held by 14 investors tracked by Insider Monkey, down from 21 a quarter before. Among the most prominent investors holding this stock was Samuel Isaly‘s OrbiMed Advisors. According to its latest 13F filing, the fund held exactly 7.4 million shares, unchanged over the quarter. James H. Litinsky’s JHL Capital Group reportedly held 3 million shares of Relypsa, up by 34% from the previous quarter.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Highland Small-Cap Equity Fund | 37,000 | 0 | 37,000 | 0 | 37,000 | 0.1% |
| Highland Capital Management Fund Advisors | 0 | 37,000 | 0 | 37,000 | 37,000 | 0.1% |
| Strand Advisors XVI, Inc | 0 | 37,000 | 0 | 37,000 | 37,000 | 0.1% |
| NexPoint Credit Strategies Fund | 2,600,000 | 0 | 2,600,000 | 0 | 2,600,000 | 5.8% |
| NexPoint Advisors | 0 | 2,600,000 | 0 | 2,600,000 | 2,600,000 | 5.8% |
| NexPoint Advisors GP | 0 | 2,600,000 | 0 | 2,600,000 | 2,600,000 | 5.8% |
| Highland Select Equity Master Fund | 3,277,900 | 0 | 3,277,900 | 0 | 3,277,900 | 7.3% |
| Highland Select Equity Fund GP | 0 | 3,277,900 | 0 | 3,277,900 | 3,277,900 | 7.3% |
| Highland Select Equity GP | 0 | 3,277,900 | 0 | 3,277,900 | 3,277,900 | 7.3% |
| Highland Capital Management | 0 | 3,277,900 | 0 | 3,277,900 | 3,277,900 | 7.3% |
| Strand Advisors, Inc | 0 | 3,277,900 | 0 | 3,277,900 | 3,277,900 | 7.3% |
| James D. Dondero | 0 | 5,914,900 | 0 | 5,914,900 | 5,914,900 | 13.2% |
Page 1 of 21 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Relypsa, Inc.
(Name of Issuer)
Common stock, par value $0.001 per share
(Title of Class of Securities)
75931106
(CUSIP Number)
July 27, 2016
(Date of Event Which Requires Filing of this Statement)
Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:
x Rule
13d-1(b)
¨ Rule 13d-1(c)
¨ Rule 13d-1(d)
